Eli Lilly and Company is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Eli Lilly and Company is a pharmaceutical company that researches and manufactures treatments for diabetes, cancer, depression, heart disease, and other illnesses. It is known for being the first company to commercialize insulin, which treats diabetes, and for Prozac, which treats depression. Other breakthrough medicines include Trulicity, which treats diabetes, and Verzenio, which treats cancer.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Eli Lilly and Company is a net-positive Humankind Value company. Notable sources of positive value include Healthcare R&D ($335.9 B), Pharmaceuticals ($19.2 B), and Economic Value ($8.2 B). Of the companies we have analyzed, Eli Lilly and Company is in the top ten for Healthcare R&D and for Pharmaceuticals. The value associated with this company’s Healthcare R&D and Pharmaceutical work is linked to an estimate of 6,800,000 additional years lived by people worldwide. The Humankind Value of this company could improve with reductions in Biofuel Production (-$3.8 B) and Greenhouse Gases (-$1.1 B). Eli Lilly and Company’s direct business activities are responsible for its Healthcare R&D, Pharmaceutical, Economic Value, and Greenhouse Gas impacts. Its effect on Biofuel Production is mostly or entirely a result of supply-chain relationships.